Waters launches SARS-CoV-2 LC-MS Kit (RUO) for clinical research of infectious diseases

New LC-MS method offers a versatile research tool in the fight against SARS-CoV-2 as it enables reproducible results with three unique peptide biomarkers

Waters Corporation introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARSCoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.

For biomedical and clinical research laboratories that are involved in fighting the pandemic, this kit offers a useful research tool for deeper study of the virus and the versatility to enable pioneering research of other infectious pathogens. The accelerated development of this method shows what's possible through collaboration and represents an important step towards equipping scientists around the world with a highly versatile, reproducible, and quantitative platform capable of providing new insights into this and future pandemics, said Dr Udit Batra, CEO and President, Waters Corporation.